Strategic alliance

Innoviva Completes Acquisition of Entasis Therapeutics

Retrieved on: 
Monday, July 11, 2022
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Strategic alliance, Regulation of tobacco by the U.S. Food and Drug Administration, Fluticasone furoate/umeclidinium bromide/vilanterol, U.S. Securities and Exchange Commission, Food, LLC, Company, Note, Forward-looking statement, Nasdaq, Acquisition, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., GlaxoSmithKline, GSK, TRC, SEC, Security (finance), Pharmaceutical industry, Entasis

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (Entasis), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.

Key Points: 
  • Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (Entasis), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.
  • Through the acquisition of Entasis, Innoviva has gained an exciting pipeline, created a new growth channel and diversified its revenue stream, said Pavel Raifeld, Chief Executive Officer of Innoviva.
  • All of the conditions of the offer have been satisfied and Innoviva completed its acquisition of all the issued and outstanding equity securities of Entasis not already owned by Innoviva and its affiliates for $2.20 per share.
  • As a result of the acquisition, Entasis became a wholly-owned subsidiary of Innoviva.

Innoviva to Acquire La Jolla Pharmaceutical Company

Retrieved on: 
Monday, July 11, 2022
Health, Pharmaceutical, COMMON, FDA, Multiplicity of infection, Septic, Attention, LLP, LLC, Schedule TO, II, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., TRC, Blood pressure, Philippe Ciais, Fluticasone furoate/umeclidinium bromide/vilanterol, U.S. Securities and Exchange Commission, Tetracycline, LA, Distributive shock, Infection, Patient, SEC, Growth, Strategic alliance, Tower of Power (transmitter), EACH, Schedule, Food, Company, Patent, Nasdaq, Report, Security (finance), Angiotensin, Industry, Criticism of the Food and Drug Administration, Gibson, Dunn & Crutcher, Risk, TIME, Acquisition, Letter of transmittal, GlaxoSmithKline, GSK, VWAP, Letter, Willkie Farr & Gallagher, Pharmaceutical industry, Risk management, Cryptocurrency

(Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.

Key Points: 
  • (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
  • We look forward to welcoming the La Jolla team to Innoviva and building upon the success of GIAPREZA and XERAVA.
  • We are pleased to announce the acquisition of La Jolla by Innoviva, which we believe provides our stockholders with immediate value at a compelling premium, said Larry Edwards, President and Chief Executive Officer of La Jolla.
  • La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

Innoviva to Acquire La Jolla Pharmaceutical Company

Retrieved on: 
Monday, July 11, 2022
Health, Infectious Diseases, General Health, Pharmaceutical, Cardiology, Biotechnology, COMMON, FDA, Multiplicity of infection, Septic, Attention, LLP, LLC, Schedule TO, Multimedia, II, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., TRC, Blood pressure, Philippe Ciais, Fluticasone furoate/umeclidinium bromide/vilanterol, U.S. Securities and Exchange Commission, Tetracycline, LA, Distributive shock, Infection, Patient, SEC, Growth, Strategic alliance, Tower of Power (transmitter), EACH, Schedule, Food, Company, Patent, Nasdaq, Report, Security (finance), Angiotensin, Industry, Criticism of the Food and Drug Administration, Gibson, Dunn & Crutcher, Risk, TIME, Acquisition, Letter of transmittal, GlaxoSmithKline, GSK, VWAP, Letter, Willkie Farr & Gallagher, Pharmaceutical industry, Risk management, Cryptocurrency

Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.

Key Points: 
  • Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
  • We look forward to welcoming the La Jolla team to Innoviva and building upon the success of GIAPREZA and XERAVA.
  • We are pleased to announce the acquisition of La Jolla by Innoviva, which we believe provides our stockholders with immediate value at a compelling premium, said Larry Edwards, President and Chief Executive Officer of La Jolla.
  • La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

Retrieved on: 
Friday, July 8, 2022
Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, Securities Exchange Act of 1934, GSK, TRC, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Exercise, Strategic alliance, Goal, Analysis, U.S. Securities and Exchange Commission, Fluticasone furoate/umeclidinium bromide/vilanterol, Entasis, Tax, Data analysis, Nasdaq, LLC, Private Securities Litigation Reform Act, Communication, Financial condition report, Result, GlaxoSmithKline, Coronavirus, Security (finance), Pharmaceutical industry

The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 11,671,662 shares of Entasis common stock were validly tendered and not withdrawn in the tender offer.

Key Points: 
  • The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 11,671,662 shares of Entasis common stock were validly tendered and not withdrawn in the tender offer.
  • Such shares of Entasis common stock, upon excluding those tendered by Manoussos Perros (the Entasis CEO), represent approximately 60.45% of the shares not beneficially owned by Innoviva and its subsidiaries or the Entasis CEO, which satisfied the minimum condition for the tender offer.
  • Innovivas wholly owned subsidiary will accept for payment all shares that were validly tendered and not withdrawn prior to expiration of the tender offer, and payment for such shares will be made promptly, in accordance with the terms of the tender offer.
  • Innoviva expects the merger to close on July 11, 2022, with Entasis becoming a wholly owned subsidiary of Innoviva.

U.S. Small Business Administration Announces Landmark Collaboration with Historically Black Fraternities and Sororities to Address the Wealth Gap Through Black Entrepreneurship

Retrieved on: 
Tuesday, June 14, 2022
Historically black colleges and universities, Community, Forgiveness, American Dreams, Strategic alliance, New York State Small Business Development Center, Human, SAM, COVID, National Pan-Hellenic Council, American Rescue Plan Act of 2021, Partnership, Corporal to Field Officer, Topical steroid withdrawal, Gaps, Government, Central business district, Mentorship, PPP, Organization, NPHC, Howard University, Growth, GLOBE, WBC, Small business, White blood cell, Support, SBA, Council of Presidents, Mammoth Resource Partners, Communication, navigation and surveillance, African Americans, SCORE, Federation, History, Minority-serving institution, National, Sam Richter, Master, Council, Management, Property management, University

This collaboration will give NPHC members critical access to information that will promote small business growth and create jobs in all sectors of our economy.

Key Points: 
  • This collaboration will give NPHC members critical access to information that will promote small business growth and create jobs in all sectors of our economy.
  • The NPHC represents the following organizations:
    The SBA Has Deepened its Engagement and Support of African American, Black and Historically Disadvantaged Small Business Owners.
  • The U.S. Small Business Administration helps power the American dream of business ownership.
  • The purpose is to foster cooperative actions of its members in dealing with matters of mutual concern.

Innoviva to Acquire Entasis Therapeutics

Retrieved on: 
Monday, May 23, 2022
GSK, Food, Infection, U.S. Securities and Exchange Commission, Schedule TO, Report, NDA, Willkie Farr & Gallagher, SEC, LLC, AstraZeneca, WHEN, Patent, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Acquisition, GLOBE, Company, Fluticasone furoate/umeclidinium bromide/vilanterol, TRC, Schedule, Gram, Attention, TIME, Security (finance), Letter, Covington & Burling, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, Patient, LLP, GlaxoSmithKline, Personal Information Agent, Strategic alliance, Risk management, Pharmaceutical industry, Financial adviser, Pseudomonas, Entasis

Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock.

Key Points: 
  • Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock.
  • The transaction has been unanimously approved by the Innoviva and Entasis Boards of Directors.
  • Innoviva has been a strategic investor in Entasis since 2020 and holds an equity stake of approximately 60% of the outstanding shares of Entasis common stock.
  • Trademark reference: Innoviva and the Innoviva logo are registered trademarks or trademarks of Innoviva, Inc. or its affiliates in the United States and/or other countries.

Innoviva to Acquire Entasis Therapeutics

Retrieved on: 
Monday, May 23, 2022
Biotechnology, Pharmaceutical, Health, GSK, Food, Infection, U.S. Securities and Exchange Commission, Schedule TO, Report, NDA, Willkie Farr & Gallagher, SEC, LLC, AstraZeneca, WHEN, Patent, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Acquisition, Company, Fluticasone furoate/umeclidinium bromide/vilanterol, TRC, Schedule, Gram, Attention, TIME, Security (finance), Letter, Covington & Burling, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, Patient, LLP, GlaxoSmithKline, Personal Information Agent, Strategic alliance, Risk management, Pharmaceutical industry, Financial adviser, Pseudomonas, Entasis

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (Entasis), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash.

Key Points: 
  • Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (Entasis), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash.
  • The transaction has been unanimously approved by the Innoviva and Entasis Boards of Directors.
  • Innoviva has been a strategic investor in Entasis since 2020 and holds an equity stake of approximately 60% of the outstanding shares of Entasis common stock.
  • Trademark reference: Innoviva and the Innoviva logo are registered trademarks or trademarks of Innoviva, Inc. or its affiliates in the United States and/or other countries.

CloudFabrix's RDAF and AIOps conference highlights the need for unifying Observability, AIOps and Intelligent Data Automation

Retrieved on: 
Wednesday, May 11, 2022
Business, Runbook, Metadata, Infrastructure as a service, Platform as a service, Data fabrication, Technology, AI, RDAF, Risk, Adobe, Digital transformation, Ecosystem, No, Health care, Intelligence, Instana, MinIO, Cisco DevNet, Automation, ITSM, CXO, IBM, ROI, Software as a service, MTTR, Heart, PII, Automotive industry, Mean Time, Interest, Artificial Intelligence for IT Operations, Compliance, Leadership, Marketing, No Code, Google, Digital, SAP, Data, KPI, Public sector, IBM Global Services, Strategic alliance, ServiceNow, Cisco Systems, Conference, TCO, Network equipment, Medical device, Software, AppDynamics, Turbonomic, Observability, Hybrid, ThousandEyes, Incident

PLEASANTON, Calif., May 11, 2022 /PRNewswire/ -- CloudFabrixä, the leader in Robotic Data Automation driven AIOps, along with Global Big Data Conference concluded Industry's 1st RDAF and AIOps conference, across eight engaging panel sessions. The thought leadership conference was focused on defining what it means to be an Autonomous Enterprise, the different levels of autonomy, the data challenges and how enterprises can build a roadmap to embark on this journey.

Key Points: 
  • PLEASANTON, Calif., May 11, 2022 /PRNewswire/ -- CloudFabrix, the leader in Robotic Data Automation driven AIOps, along with Global Big Data Conference concluded Industry's 1st RDAF and AIOps conference, across eight engaging panel sessions.
  • RDAF brings self-service automation capabilities by unifying Observability, AIOps and Automation with a low-code Data and ML Bots approach.
  • CloudFabrix's RDAF platform is architected to mitigate these challenges with Data automation, No code/low code Databots and Data Fabric and applying them to Observability, AIOps and Automation.
  • We strongly believe RDAF as market category enables enterprises to embark on their Autonomous Enterprise journey, unifying Observability, AIOps and Automation.

Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Pharmaceutical, Health, Solution, U.S. Securities and Exchange Commission, CEO, Patient, Annual report, COVID-19, Quality of life, AD, New Drug Application, Strategic alliance, Azathioprine, Company, Autoimmunity, Therapy, Security (finance), Multimedia, Marketing, Research, Shanda, NASDAQ, JAK, JAK2, Ciclosporin, Knowledge, Vitiligo, MAA, Atopic dermatitis, Inflammation, Health, Disease, Hidradenitis suppurativa, Safety, Pharmaceutical industry, Vaccine, Cosmetics, Incyte, Dermatology

Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incytes selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan.

Key Points: 
  • Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incytes selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan.
  • Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan.
  • Maruho President and CEO, Atsushi Sugita said, "Incyte has successfully launched ruxolitinib cream in the U.S. and provided a new treatment for patients suffering from atopic dermatitis.
  • As a specialty pharmaceutical company in dermatology aimed at improving the lives of patients, supporting the development of ruxolitinib cream has great significance for Maruho.

Innoviva Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, April 27, 2022
Biotechnology, Pharmaceutical, Health, Financial condition report, U.S. Securities and Exchange Commission, Result, Securities Exchange Act of 1934, Income, LLC, Investment, TRC, LABA, Data analysis, Private Securities Litigation Reform Act, Growth, Traction, Strategic alliance, Company, Goal, Security (finance), Communication, Analysis, GSK, NASDAQ, Coronavirus, Environment, Fluticasone furoate/umeclidinium bromide/vilanterol, GlaxoSmithKline, Video game, Pharmaceutical industry, Entasis, Armata, EU

Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company) today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company) today reported financial results for the first quarter ended March 31, 2022.
  • Decrease in fair values of equity and long-term investments of $9.4 million in the first quarter of 2022 was mainly due to the volatility in the capital markets.
  • Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: "Our royalty revenues in the first quarter grew 5% year over year, displaying strong positive momentum in a volatile, pandemic-influenced environment."
  • RELVAR/BREO ELLIPTA global net sales decreased slightly compared to first quarter 2021 with 4% U.S. net sales growth compensating for a slowdown in non-U.S. markets.